Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954842 | 0.85 | HRH3 (0.45) | HRH3CSNK1DMAPK14HPGDHSD17B10 | |
| SCHEMBL2954143 | 0.73 | MAPK14 (0.60) | GLACSNK1DMAPK14MAPK11 | |
| Hydrochloric Acid SCHEMBL2955401 | 0.72 | MAPK14 (0.58) | CSNK1DMAPK14MAPK11 | |
| SCHEMBL2958555 | 0.71 | HPGD (0.40) | GLACSNK1DMAPK14MAPK11HPGD | |
| SCHEMBL2957272 | 0.71 | HPGD (0.40) | GLACSNK1DMAPK14MAPK11HPGD | |
| SCHEMBL2957347 | 0.71 | KDM4E (0.46) | HRH3GLACSNK1DMAPK14MAPK11 | |
| SCHEMBL2957199 | 0.67 | HTR7 (0.41) | L3MBTL1CSNK1DMAPK14HSD17B10RAB9A | |
| SCHEMBL27786505 | 0.66 | CSNK1D (0.40) | CSNK1DMAPK14MAPK11HPGDHSD17B10 | |
| SCHEMBL2958371 | 0.65 | CKS1B (0.55) | — | |
| Tert-Butyl Formate SCHEMBL27786506 | 0.65 | MAPK14 (0.48) | CSNK1DMAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | HRH3 1131/4885L3MBTL3 4426/4885L3MBTL1 4200/4885 |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | HRH3 1131/4885L3MBTL3 4426/4885L3MBTL1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.